FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Medline Industries QS Violations Cited

FDA warns Glens Falls, NY-based Medline Industries about Quality System violations in its manufacturing and assembly of cardiovascular procedure kits.

latest-news-card-1
Medical Devices

FDA Opens READI-Home Innovation Challenge

FDA solicits applications for its new READI-Home innovation challenge to use medical technology in the home to reduce or prevent hospital readmissions...

latest-news-card-1
Human Drugs

Groups Urge Congress to Advance Generic Drug Bills

Healthcare advocacy organizations call on key House lawmakers to hold hearings and advance bipartisan legislation aimed at lowering prescription drug ...

latest-news-card-1
Human Drugs

FDA Grants Outlook Therapeutics Dispute Resolution Request

FDA agrees to hear an Outlook Therapeutics formal dispute resolution request regarding the agencys prior rejection of eye disease therapy Lytenava (be...

latest-news-card-1
Human Drugs

Federal Judge Pauses Challenge to Abortion Pill Rules

A federal judge declines to immediately restrict access to the abortion pill mifepristone, instead pausing a high-profile lawsuit brought by Louisiana...

Human Drugs

Support for Rare Disease Education Materials

Three stakeholders express support for FDAs LEADER 3D rare disease educational materials and suggest ways to improve them.

latest-news-card-1
FDA General

FDA Budget Request Seeks 3% Increase

FDAs just-released proposed fiscal year 2027 budget seeks a 3.3% increase or about $200 million to fund the agencys operations.

Medical Devices

FDA Patient Preference Guide Addresses 510(k) Applicability

FDAs updated guidance on how patient preference information can be incorporated into regulatory decision-making for medical devices and biologics appe...

latest-news-card-1
Biologics

Positive Phase 3 Date for Subcutaneous Tepezza: Amgen

Amgen reports positive topline results from a Phase 3 trial evaluating a subcutaneous version of its thyroid eye disease drug Tepezza (teprotumumab-tr...

latest-news-card-1
Human Drugs

ImmunityBio Responds to FDA Concerns Over Promotional Materials

ImmunityBio says it has responded to FDAs recent Warning Letter on the companys alleged misleading promotional claims about its cancer therapy Anktiva...